Sagimet Biosciences Inc.

Sagimet Biosciences Inc. reported a net loss of $51.0 million for fiscal year 2025, driven by total operating expenses of $56.9 million, which consisted of $39.1 million in research and development expenses and $17.8 million in general and administrative expenses. The company's loss from operations was $56.9 million, partially offset by other income of $5.9 million, primarily from interest income. The net loss per share was $2.00 for both basic and diluted calculations, based on weighted-average shares outstanding of 32.3 million. The company's total comprehensive loss was $51.1 million, which includes a net unrealized loss on marketable securities of $110,000. On the balance sheet, total assets stood at $116.5 million, with current assets of $116.4 million including cash and cash equivalents of $35.0 million and short-term marketable securities of $78.1 million. Total liabilities were $5.1 million, resulting in stockholders' equity of $111.4 million. Cash flow from operations was negative $45.6 million, while investing activities provided $4.6 million and financing activities contributed $275,000, leading to a net decrease in cash of $40.8 million.

Key Takeaways